Page last updated: 2024-11-07

schizandrin b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Schizandrin B is a lignan compound isolated from the fruit of the Chinese medicinal plant Schisandra chinensis. It has been shown to possess a variety of pharmacological activities, including antioxidant, anti-inflammatory, hepatoprotective, neuroprotective, and anticancer effects. The compound is believed to exert its effects through a number of mechanisms, including modulation of intracellular signaling pathways, inhibition of oxidative stress, and enhancement of antioxidant defenses. Schizandrin B is of particular interest to researchers due to its potential therapeutic benefits in a range of conditions, including liver disease, neurodegenerative disorders, and cancer. Research on schizandrin B continues to explore its therapeutic potential and to elucidate its mechanisms of action.'

schizandrin B: a phytogenic antineoplastic agent with anti-inflammatory activity; isolated from Schisandra plant [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(+)-schisandrin B : An organic heterotetracyclic compound that is found in Fructus Schisandrae and Schisandra chinensis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID108130
CHEMBL ID479488
SCHEMBL ID3380716
MeSH IDM0064804
PubMed CID158103
CHEMBL ID402435
CHEBI ID132471
CHEBI ID4410
SCHEMBL ID713266
MeSH IDM0064804

Synonyms (84)

Synonym
schizandrin b
schisandrin b
NCGC00163663-01
61281-37-6
1,2,3,13-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydrobenzo[3',4']cycloocta[1',2':4,5]benzo[1,2-d][1,3]dioxole
SCHEMBL3380716
CHEMBL479488 ,
bdbm50341711
AKOS015897166
CCG-208607
CS-3659
Q-100707
schizandrin-b
HY-N0089
s(-) schisandrin b
HMS3652I13
SR-05000002175-2
sr-05000002175
|a-schisandrin
gamma-schisandrin ,(s)
schisandrin b; wuweizisu-b; gamma-schisandrin
BCP30085
benzo[3,4]cycloocta[1,2-f][1,3]benzodioxole,5,6,7,8-tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethyl-, stereoisomer
1,2,3,13-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydro-11h-benzo[3',4']cycloocta[1',2':4,5]benzo[1,2-d][1,3]dioxole
DTXSID60976772
schizandrin-b;wuweizisu-b;gamma-schisandrin
FT-0775855
(5s,6s,7s,13as)-5,6,7,8-tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethylbenzo[3,4]cycloocta[1,2-f][1,3] benzodioxole-5,6-diol 5-benzoate
GLXC-19128
3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaene
s(-) wuweizisu b
AC-20310
benzo(3,4)cycloocta(1,2-f)(1,3)benzodioxole, 5,6,7,8-tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethyl-, stereoisomer
gamma-schisandrin
gamma-schizandrin
wuweizisu b
(+)-gamma-schizandrin
deoxygomisin a
82467-52-5
gomisin n
(-)-gomisin n
benzo(3,4)cycloocta(1,2-f)(1,3)benzodioxole, 5,6,7,8-tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethyl-, (6r,7s,13ar)-
benzo(3,4)cycloocta(1,2-f)(1,3)benzodioxole, 5,6,7,8-tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethyl-, (6r,7s,13as)-
CHEBI:132471
(+)-schizandrin b
(6r,7s13ar)-1,2,3,13-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydro-11h-benzo[3',4']cycloocta[1',2':4,5]benzo[1,2-d][1,3]dioxole
(+)-schisandrin b
chebi:4410 ,
CHEMBL402435
FT-0650806
AC1L4JAK ,
dko6o75z5v ,
unii-dko6o75z5v
69176-52-9
isokadsuranin
AKOS015965220
unii-02xa4x3kzw
02xa4x3kzw ,
SCHEMBL713266
DTXSID10231747
RTZKSTLPRTWFEV-OLZOCXBDSA-N
AC-34238
AC-34828
gomisin-n
(6r,7s,13as)-5,6,7,8-tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethylbenzo(3,4)cycloocta(1,2-f)(1,3)benzodioxole
( )-schisandrin b
.gamma.-schisandrin
(+/-)-.gamma.-schizandrin
schisandrin b (.gamma.-schisandrin) (constituent of northern schisandra) [dsc]
.gamma.-schizandrin
benzo(3,4)cycloocta(1,2-f)(1,3)benzodioxole, 5,6,7,8-tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethyl-, (6r,7s,13ar)-rel-
(+/-)-.gamma.-schisandrin
schisandrin b, (+/-)-
CS-0027857
HY-N6866
1,2,3,12-tetramethoxy-6,7-dimethyl- 10,11-methylenedioxy-5,6,7,8-tetrahydrodibenzo[a,c]cyclooctene
(9r,10s)-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaene
MS-26802
bdbm50595039
E80780
CS-0019596
HY-N2267
E87117
(6r,7s)-1,2,3,13-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydrobenzo[3',4']cycloocta[1',2':4,5]benzo[1,2-d][1,3]dioxole

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Further investigation indicated that pretreatment with TP and Sch B significantly reversed the toxic effects of HgCl(2)."( The protective effects of tea polyphenols and schisandrin B on nephrotoxicity of mercury.
Deng, Y; Liu, W; Wei, Y; Xu, B; Xu, Z; Yang, H, 2011
)
0.37
"Renal proximal tubular epithelial cells are the main targets of toxic drugs such as cisplatin (CisPt), an alkylating agent indicated for the treatment of solid organ tumors."( Protective effects of schizandrin and schizandrin B towards cisplatin nephrotoxicity in vitro.
Antoine, MH; Bunel, V; Duez, P; Nortier, J; Stévigny, C, 2014
)
0.67
" However, the potential hepatotoxicity of Sch B is a major safety concern, and the underlying mechanism for Sch B-induced liver toxic effects is not fully elucidated."( Schisandrin B inhibits cell growth and induces cellular apoptosis and autophagy in mouse hepatocytes and macrophages: implications for its hepatotoxicity.
He, ZX; Hu, C; Jin, H; Ko, KM; Pan, SY; Yang, T; Yu, ZL; Zhang, X; Zhang, Y; Zhou, SF; Zhou, ZW, 2015
)
0.42
" Therefore, there is an urgent need to provide safe and effective treatment for patients."( Study on the Protective Effect of Schizandrin B against Acetaminophen-Induced Cytotoxicity in Human Hepatocyte.
Cao, Y; Cheng, L; Gao, Z; Wang, L; Wang, T; Wu, W; Zhang, Q, 2022
)
1
" SchB diet effectively alleviated these adverse reactions."( Schisandrin B Diet Inhibits Oxidative Stress to Reduce Ferroptosis and Lipid Peroxidation to Prevent Pirarubicin-Induced Hepatotoxicity.
Pu, P; Shi, H; Tang, H; Yan, Y; Yang, H, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" In this work, plasma pharmacokinetic characteristics of lignans components after oral administration SMS were investigated using UPLC-Q-TOF/MS method."( Pharmacokinetic study of schisandrin, schisandrol B, schisantherin A, deoxyschisandrin, and schisandrin B in rat plasma after oral administration of Shengmaisan formula by UPLC-MS.
Han, Y; Sun, H; Wang, X; Wei, W; Wu, F; Zhang, A, 2013
)
0.39
" This paper was designed to study on the plasma pharmacokinetic for its absorption process, and to compare the pharmacokinetics of its active ingredients in normal and insomnic rats orally administrated with the prescription."( Development of a UFLC-MS/MS method for simultaneous determination of six lignans of Schisandra chinensis (Turcz.) Baill. in rat plasma and its application to a comparative pharmacokinetic study in normal and insomnic rats.
Bi, K; Chen, X; Fan, R; Geng, L; He, B; Jia, Y; Li, Q; Su, D; Wei, B; Zhao, L, 2013
)
0.39
" The pharmacokinetic curve showed double peaks after oral administration, which demonstrated that a hepatoenteral circulation may exist."( Pharmacokinetics and tissue distribution study of schisandrin B in rats by ultra-fast liquid chromatography with tandem mass spectrometry.
Cui, B; Guan, J; Zhang, X; Zhao, L; Zhao, X; Zhu, H, 2013
)
0.39
" The parameters area under the plasma concentration-time curve from time zero to the final measurable point and from time zero to infinity, and peak concentration were significantly increased, with a prolonged mean residence time and a corresponding decrease in clearance in comparision with the Schisandra-alone group."( Comparative pharmacokinetics and tissue distribution of schisandrin, deoxyschisandrin and schisandrin B in rats after combining acupuncture and herb medicine (schisandra chinensis).
Dai, G; Ji, D; Li, L; Lu, T; Mao, C; Sun, Y; Wu, X; Xu, B; Yin, F; Zhou, Y, 2014
)
0.4
" After oral administration of FZHY at a dose of 15g/kg, the pharmacokinetic behaviors of schizandrin A (SIA), schizandrin B (SIB), schizandrin C (SIC), schisandrol A (SOA), Schisandrol B (SOB) and schisantherin A (STA) have been significantly changed in hepatic fibrosis rats compared with the normal rats, and their AUC(0-t) values were increased by 235."( Comparative pharmacokinetics and tissue distribution profiles of lignan components in normal and hepatic fibrosis rats after oral administration of Fuzheng Huayu recipe.
Liu, CH; Liu, S; Tao, YY; Yang, T; Zheng, TH, 2015
)
0.63
"9 g/kg SY, nifedipine clearance decreased by 34% and half-life increased by 142%."( Shenmai-Yin decreased the clearance of nifedipine in rats: The involvement of time-dependent inhibition of nifedipine oxidation.
Chen, AC; Chen, WC; Lu, CK; Ueng, YF; Wang, HJ, 2019
)
0.51

Bioavailability

ExcerptReferenceRelevance
" The main purpose of this work is to prepare self-emulsifying drug delivery systems (SEDDS) for enhancing the solubility, dissolution rate, and oral bioavailability of poorly water-soluble traditional Chinese medicines, Wurenchun."( Enhanced oral bioavailability of Wurenchun (Fructus Schisandrae Chinensis extracts) by self-emulsifying drug delivery systems.
Ji, H; Liu, H; Liu, Y; Shao, B; Tang, J; Wu, L; Zhu, D, 2010
)
0.36
" The attenuated hepatoprotection afforded by curcumin may be attributed to its low bioavailability in vivo."( Prooxidant-induced glutathione antioxidant response in vitro and in vivo: a comparative study between schisandrin B and curcumin.
Chiu, PY; Ko, KM; Leong, PK, 2012
)
0.38
" These results suggested that 3-day treatment of Sch B could increase concentration and oral bioavailability of drug metabolized by CYP3A."( In vivo effect of Schisandrin B on cytochrome P450 enzyme activity.
Li, WL; Wu, XC; Xin, HW; Yu, AR, 2013
)
0.39
" With SchB suspensions as the reference formulation, the relative bioavailability of SchB-F-LPNs was 568."( [Preparation and evaluation of schisandrin B-loaded F127 modified lipid-polymer nanoparticles for inhibition of breast cancer lung metastasis].
Fei, Y; Hai-Zhen, C; Jiang-Pei, S; Jun-Yi, S; Nian-Ping, F; Xiao-Yan, GU; Xing-Mei, X; Ying, L; Zi-Fei, J, 2020
)
0.56
" It suggested that the potential interactions of SMS with CYP 3A drug substrates should be noticed, especially the drugs whose bioavailability depends heavily on intestinal CYP3A."( Effects of Shengmai San on key enzymes involved in hepatic and intestinal drug metabolism in rats.
Chia-Hui Tan, E; Chiang, TY; Lee, IJ; Ueng, YF; Wang, HJ; Wang, YC; Yun, CH, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
") increased the hepatic mitochondrial-reduced glutathione (GSH) level, BHT treatment at the same dosage regimen decreased it."( The crucial antioxidant action of schisandrin B in protecting against carbon tetrachloride hepatotoxicity in mice: a comparative study with butylated hydroxytoluene.
Ip, SP; Ko, KM, 1996
)
0.29
" Pretreating mice with Sch A at a daily oral dose of 1 mmol/kg for 3 days did not protect against CCl4 hepatotoxicity, whereas pretreatment with Sch B or Sch C at the same dosage regimen produced almost complete protection."( Methylenedioxy group as determinant of schisandrin in enhancing hepatic mitochondrial glutathione in carbon tetrachloride-intoxicated mice.
Che, CT; Ip, SP; Ko, KM; Ma, CY, 1997
)
0.3
"2 mmol/kg for 3 days did not protect the isolated-perfused hearts against IR-induced damage, pretreatment with Sch B or Sch C at the same dosage regimen produced cardioprotective action."( Methylenedioxy group and cyclooctadiene ring as structural determinants of schisandrin in protecting against myocardial ischemia-reperfusion injury in rats.
Ko, KM; Yim, TK, 1999
)
0.3
" Pretreating mice with Sch B or DDB at the same dosage regimen significantly suppressed the CCl4-induced increase in plasma ALT activity, with the inhibitory effect of Sch B being much more potent."( Differential effect of schisandrin B and dimethyl diphenyl bicarboxylate (DDB) on hepatic mitochondrial glutathione redox status in carbon tetrachloride intoxicated mice.
Ip, SP; Ko, KM; Yiu, HY, 2000
)
0.31
" In rats treated with Sch B and HgCl2, HSP72, HSP25 and MTs were overexpressed in liver zones 1 and 3 irrespective of HgCl2 dosing schedules."( Schisandrin B stimulates a cytoprotective response in rat liver exposed to mercuric chloride.
Lavazza, A; Li Volti, G; Rezzani, R; Rodella, LF; Stacchiotti, A, 2009
)
0.35
" Also, there might be potential interactions between SLE or DDB and co-administered medicines and it is necessary to adjust the dosage of co-administrated medicines in clinical medication of liver disease."( Reversing effects of lignans on CCl4-induced hepatic CYP450 down regulation by attenuating oxidative stress.
Guo, C; Hao, H; Kang, A; Wang, G; Wang, H; Xie, Y, 2014
)
0.4
" This study was conducted to compare the time- and dose-response between Sch B- and SF oil (SFO)-induced changes in hepatic and serum parameters in mice."( Time and dose relationships between schisandrin B- and schisandrae fructus oil-induced hepatotoxicity and the associated elevations in hepatic and serum triglyceride levels in mice.
Chu, ZS; Ko, KM; Pan, SY; Sun, N; Wang, XY; Yu, ZL; Zhang, Y; Zhou, SF; Zhu, PL, 2014
)
0.4
" Six lignans pretreatment before APAP dosing could prevent the depletions of total liver glutathione (GSH) and mitochondrial GSH caused by APAP."( Hepato-protective effects of six schisandra lignans on acetaminophen-induced liver injury are partially associated with the inhibition of CYP-mediated bioactivation.
Bi, H; Chen, P; Fan, X; Huang, M; Jiang, Y; Tan, H; Wang, Y; Zeng, H, 2015
)
0.42
" The results showed\ that pretreatment with a lower dosage of Sch B (25, 50 mg·kg−1) prevented CLZ-induced liver injury as indicated\ by the reduced levels of ALT, AST and ALP, and the preserved activities of SOD, GSH and inhibiting MDA."( [Protection effects of schizandrin B against liver injury induced by clozapine in mice].
Bai, HY; Feng, S, 2017
)
0.77
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (9)

RoleDescription
nephroprotective agentAny protective agent that is able to prevent damage to the kidney.
apoptosis inhibitorAny substance that inhibits the process of apoptosis (programmed cell death) in multi-celled organisms.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
anti-asthmatic agentAny compound that has anti-asthmatic effects.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
anti-inflammatory agentAny compound that has anti-inflammatory effects.
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
hepatoprotective agentAny compound that is able to prevent damage to the liver.
antilipemic drugA substance used to treat hyperlipidemia (an excess of lipids in the blood).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
organic heterotetracyclic compound
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
oxacycleAny organic heterocyclic compound containing at least one ring oxygen atom.
cyclic acetalAn acetal in the molecule of which the acetal carbon and one or both oxygen atoms thereon are members of a ring.
tanninAny of a group of astringent polyphenolic vegetable principles or compounds, chiefly complex glucosides of catechol and pyrogallol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA-dependent protein kinase catalytic subunitHomo sapiens (human)IC50 (µMol)1,000,000.00000.00051.350010.0000AID593233
Serine-protein kinase ATMHomo sapiens (human)IC50 (µMol)1,740.00000.00200.29173.4200AID593232
Serine/threonine-protein kinase ATRHomo sapiens (human)IC50 (µMol)7.25000.00301.29487.3000AID593187; AID705439
Glycogen synthase kinase-3 betaHomo sapiens (human)IC50 (µMol)0.07300.00060.801310.0000AID1872905
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (183)

Processvia Protein(s)Taxonomy
peptidyl-serine phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
maturation of 5.8S rRNADNA-dependent protein kinase catalytic subunitHomo sapiens (human)
somitogenesisDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
negative regulation of protein phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
activation of innate immune responseDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
B cell lineage commitmentDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
immature B cell differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
pro-B cell differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
T cell lineage commitmentDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
double-strand break repairDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
double-strand break repair via nonhomologous end joiningDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
chromatin remodelingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA damage responseDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
brain developmentDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
heart developmentDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
response to gamma radiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
telomere cappingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
peptidyl-serine phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
peptidyl-threonine phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
mitotic G1 DNA damage checkpoint signalingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein destabilizationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
cellular response to insulin stimulusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
T cell differentiation in thymusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
T cell receptor V(D)J recombinationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
small-subunit processome assemblyDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
ectopic germ cell programmed cell deathDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein modification processDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of circadian rhythmDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of apoptotic processDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
negative regulation of apoptotic processDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
innate immune responseDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of lymphocyte differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of erythrocyte differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of translationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
rhythmic processDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of smooth muscle cell proliferationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of epithelial cell proliferationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
double-strand break repair via alternative nonhomologous end joiningDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
negative regulation of cGAS/STING signaling pathwayDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of hematopoietic stem cell differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of platelet formationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of double-strand break repair via nonhomologous end joiningDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
immunoglobulin V(D)J recombinationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
telomere maintenanceDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of telomerase activitySerine-protein kinase ATMHomo sapiens (human)
DNA damage responseSerine-protein kinase ATMHomo sapiens (human)
peptidyl-serine autophosphorylationSerine-protein kinase ATMHomo sapiens (human)
DNA damage checkpoint signalingSerine-protein kinase ATMHomo sapiens (human)
pexophagySerine-protein kinase ATMHomo sapiens (human)
double-strand break repair via homologous recombinationSerine-protein kinase ATMHomo sapiens (human)
DNA double-strand break processingSerine-protein kinase ATMHomo sapiens (human)
ovarian follicle developmentSerine-protein kinase ATMHomo sapiens (human)
response to hypoxiaSerine-protein kinase ATMHomo sapiens (human)
somitogenesisSerine-protein kinase ATMHomo sapiens (human)
pre-B cell allelic exclusionSerine-protein kinase ATMHomo sapiens (human)
double-strand break repairSerine-protein kinase ATMHomo sapiens (human)
double-strand break repair via nonhomologous end joiningSerine-protein kinase ATMHomo sapiens (human)
chromatin remodelingSerine-protein kinase ATMHomo sapiens (human)
protein phosphorylationSerine-protein kinase ATMHomo sapiens (human)
DNA damage responseSerine-protein kinase ATMHomo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestSerine-protein kinase ATMHomo sapiens (human)
mitotic spindle assembly checkpoint signalingSerine-protein kinase ATMHomo sapiens (human)
mitotic G2 DNA damage checkpoint signalingSerine-protein kinase ATMHomo sapiens (human)
reciprocal meiotic recombinationSerine-protein kinase ATMHomo sapiens (human)
male meiotic nuclear divisionSerine-protein kinase ATMHomo sapiens (human)
female meiotic nuclear divisionSerine-protein kinase ATMHomo sapiens (human)
signal transductionSerine-protein kinase ATMHomo sapiens (human)
brain developmentSerine-protein kinase ATMHomo sapiens (human)
heart developmentSerine-protein kinase ATMHomo sapiens (human)
determination of adult lifespanSerine-protein kinase ATMHomo sapiens (human)
post-embryonic developmentSerine-protein kinase ATMHomo sapiens (human)
response to ionizing radiationSerine-protein kinase ATMHomo sapiens (human)
regulation of autophagySerine-protein kinase ATMHomo sapiens (human)
positive regulation of gene expressionSerine-protein kinase ATMHomo sapiens (human)
peptidyl-serine phosphorylationSerine-protein kinase ATMHomo sapiens (human)
positive regulation of cell migrationSerine-protein kinase ATMHomo sapiens (human)
negative regulation of B cell proliferationSerine-protein kinase ATMHomo sapiens (human)
regulation of telomere maintenance via telomeraseSerine-protein kinase ATMHomo sapiens (human)
positive regulation of telomere maintenance via telomeraseSerine-protein kinase ATMHomo sapiens (human)
V(D)J recombinationSerine-protein kinase ATMHomo sapiens (human)
cellular response to reactive oxygen speciesSerine-protein kinase ATMHomo sapiens (human)
multicellular organism growthSerine-protein kinase ATMHomo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processSerine-protein kinase ATMHomo sapiens (human)
lipoprotein catabolic processSerine-protein kinase ATMHomo sapiens (human)
signal transduction in response to DNA damageSerine-protein kinase ATMHomo sapiens (human)
regulation of apoptotic processSerine-protein kinase ATMHomo sapiens (human)
positive regulation of apoptotic processSerine-protein kinase ATMHomo sapiens (human)
positive regulation of DNA damage response, signal transduction by p53 class mediatorSerine-protein kinase ATMHomo sapiens (human)
positive regulation of neuron apoptotic processSerine-protein kinase ATMHomo sapiens (human)
meiotic telomere clusteringSerine-protein kinase ATMHomo sapiens (human)
positive regulation of cell adhesionSerine-protein kinase ATMHomo sapiens (human)
positive regulation of transcription by RNA polymerase IISerine-protein kinase ATMHomo sapiens (human)
protein autophosphorylationSerine-protein kinase ATMHomo sapiens (human)
thymus developmentSerine-protein kinase ATMHomo sapiens (human)
oocyte developmentSerine-protein kinase ATMHomo sapiens (human)
neuron apoptotic processSerine-protein kinase ATMHomo sapiens (human)
regulation of cell cycleSerine-protein kinase ATMHomo sapiens (human)
histone mRNA catabolic processSerine-protein kinase ATMHomo sapiens (human)
cellular response to retinoic acidSerine-protein kinase ATMHomo sapiens (human)
cellular response to gamma radiationSerine-protein kinase ATMHomo sapiens (human)
cellular response to X-raySerine-protein kinase ATMHomo sapiens (human)
cellular response to nitrosative stressSerine-protein kinase ATMHomo sapiens (human)
cellular senescenceSerine-protein kinase ATMHomo sapiens (human)
replicative senescenceSerine-protein kinase ATMHomo sapiens (human)
establishment of RNA localization to telomereSerine-protein kinase ATMHomo sapiens (human)
establishment of protein-containing complex localization to telomereSerine-protein kinase ATMHomo sapiens (human)
regulation of cellular response to heatSerine-protein kinase ATMHomo sapiens (human)
regulation of signal transduction by p53 class mediatorSerine-protein kinase ATMHomo sapiens (human)
positive regulation of DNA catabolic processSerine-protein kinase ATMHomo sapiens (human)
regulation of microglial cell activationSerine-protein kinase ATMHomo sapiens (human)
negative regulation of TORC1 signalingSerine-protein kinase ATMHomo sapiens (human)
negative regulation of telomere cappingSerine-protein kinase ATMHomo sapiens (human)
positive regulation of telomere maintenance via telomere lengtheningSerine-protein kinase ATMHomo sapiens (human)
positive regulation of telomerase catalytic core complex assemblySerine-protein kinase ATMHomo sapiens (human)
regulation of autophagosome assemblySerine-protein kinase ATMHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageSerine-protein kinase ATMHomo sapiens (human)
telomere maintenanceSerine-protein kinase ATMHomo sapiens (human)
nuclear membrane disassemblySerine/threonine-protein kinase ATRHomo sapiens (human)
DNA damage checkpoint signalingSerine/threonine-protein kinase ATRHomo sapiens (human)
nucleobase-containing compound metabolic processSerine/threonine-protein kinase ATRHomo sapiens (human)
DNA replicationSerine/threonine-protein kinase ATRHomo sapiens (human)
double-strand break repairSerine/threonine-protein kinase ATRHomo sapiens (human)
chromatin remodelingSerine/threonine-protein kinase ATRHomo sapiens (human)
DNA damage responseSerine/threonine-protein kinase ATRHomo sapiens (human)
negative regulation of DNA replicationSerine/threonine-protein kinase ATRHomo sapiens (human)
response to xenobiotic stimulusSerine/threonine-protein kinase ATRHomo sapiens (human)
response to mechanical stimulusSerine/threonine-protein kinase ATRHomo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase ATRHomo sapiens (human)
replication fork processingSerine/threonine-protein kinase ATRHomo sapiens (human)
positive regulation of telomere maintenance via telomeraseSerine/threonine-protein kinase ATRHomo sapiens (human)
cellular response to UVSerine/threonine-protein kinase ATRHomo sapiens (human)
interstrand cross-link repairSerine/threonine-protein kinase ATRHomo sapiens (human)
positive regulation of DNA damage response, signal transduction by p53 class mediatorSerine/threonine-protein kinase ATRHomo sapiens (human)
mitotic G2/M transition checkpointSerine/threonine-protein kinase ATRHomo sapiens (human)
response to arsenic-containing substanceSerine/threonine-protein kinase ATRHomo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase ATRHomo sapiens (human)
protein localization to chromosome, telomeric regionSerine/threonine-protein kinase ATRHomo sapiens (human)
cellular response to gamma radiationSerine/threonine-protein kinase ATRHomo sapiens (human)
replicative senescenceSerine/threonine-protein kinase ATRHomo sapiens (human)
establishment of RNA localization to telomereSerine/threonine-protein kinase ATRHomo sapiens (human)
establishment of protein-containing complex localization to telomereSerine/threonine-protein kinase ATRHomo sapiens (human)
regulation of cellular response to heatSerine/threonine-protein kinase ATRHomo sapiens (human)
positive regulation of telomerase catalytic core complex assemblySerine/threonine-protein kinase ATRHomo sapiens (human)
regulation of double-strand break repairSerine/threonine-protein kinase ATRHomo sapiens (human)
DNA repairSerine/threonine-protein kinase ATRHomo sapiens (human)
telomere maintenanceSerine/threonine-protein kinase ATRHomo sapiens (human)
positive regulation of gene expressionGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of gene expressionGlycogen synthase kinase-3 betaHomo sapiens (human)
ER overload responseGlycogen synthase kinase-3 betaHomo sapiens (human)
peptidyl-serine phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
intracellular signal transductionGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of apoptotic processGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein export from nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
epithelial to mesenchymal transitionGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of cell-matrix adhesionGlycogen synthase kinase-3 betaHomo sapiens (human)
glycogen metabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
protein phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
mitochondrion organizationGlycogen synthase kinase-3 betaHomo sapiens (human)
dopamine receptor signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
circadian rhythmGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of autophagyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of gene expressionGlycogen synthase kinase-3 betaHomo sapiens (human)
peptidyl-serine phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
peptidyl-threonine phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
viral protein processingGlycogen synthase kinase-3 betaHomo sapiens (human)
hippocampus developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
establishment of cell polarityGlycogen synthase kinase-3 betaHomo sapiens (human)
maintenance of cell polarityGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of cell migrationGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of axon extensionGlycogen synthase kinase-3 betaHomo sapiens (human)
neuron projection developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of protein-containing complex assemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein-containing complex assemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein ubiquitinationGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of phosphoprotein phosphatase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of microtubule-based processGlycogen synthase kinase-3 betaHomo sapiens (human)
intracellular signal transductionGlycogen synthase kinase-3 betaHomo sapiens (human)
cellular response to interleukin-3Glycogen synthase kinase-3 betaHomo sapiens (human)
regulation of circadian rhythmGlycogen synthase kinase-3 betaHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of GTPase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of cell differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of osteoblast differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of glycogen biosynthetic processGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of cilium assemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein catabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
protein autophosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of protein export from nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of dendrite morphogenesisGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of axonogenesisGlycogen synthase kinase-3 betaHomo sapiens (human)
canonical Wnt signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
excitatory postsynaptic potentialGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of microtubule cytoskeleton organizationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascadeGlycogen synthase kinase-3 betaHomo sapiens (human)
superior temporal gyrus developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
cellular response to retinoic acidGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of canonical Wnt signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
extrinsic apoptotic signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandGlycogen synthase kinase-3 betaHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionGlycogen synthase kinase-3 betaHomo sapiens (human)
neuron projection organizationGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of microtubule anchoring at centrosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of cellular response to heatGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of protein localization to nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of long-term synaptic potentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of protein acetylationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein localization to ciliumGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of dopaminergic neuron differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
cellular response to amyloid-betaGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein localization to centrosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
beta-catenin destruction complex disassemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of type B pancreatic cell developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of glycogen (starch) synthase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of mesenchymal stem cell differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of TOR signalingGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of neuron projection developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
cell differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
insulin receptor signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (30)

Processvia Protein(s)Taxonomy
double-stranded DNA bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
RNA bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein serine/threonine kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA-dependent protein kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
ATP bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
enzyme bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein domain specific bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
U3 snoRNA bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
histone H2AXS139 kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein serine kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA bindingSerine-protein kinase ATMHomo sapiens (human)
protein serine/threonine kinase activitySerine-protein kinase ATMHomo sapiens (human)
DNA-dependent protein kinase activitySerine-protein kinase ATMHomo sapiens (human)
protein bindingSerine-protein kinase ATMHomo sapiens (human)
ATP bindingSerine-protein kinase ATMHomo sapiens (human)
1-phosphatidylinositol-3-kinase activitySerine-protein kinase ATMHomo sapiens (human)
histone H2AXS139 kinase activitySerine-protein kinase ATMHomo sapiens (human)
identical protein bindingSerine-protein kinase ATMHomo sapiens (human)
protein-containing complex bindingSerine-protein kinase ATMHomo sapiens (human)
protein serine kinase activitySerine-protein kinase ATMHomo sapiens (human)
DNA bindingSerine/threonine-protein kinase ATRHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase ATRHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase ATRHomo sapiens (human)
protein bindingSerine/threonine-protein kinase ATRHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase ATRHomo sapiens (human)
MutLalpha complex bindingSerine/threonine-protein kinase ATRHomo sapiens (human)
MutSalpha complex bindingSerine/threonine-protein kinase ATRHomo sapiens (human)
histone H2AXS139 kinase activitySerine/threonine-protein kinase ATRHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase ATRHomo sapiens (human)
protease bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
p53 bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein serine/threonine kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
ATP bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
beta-catenin bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
ubiquitin protein ligase bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase A catalytic subunit bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
dynactin bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
tau protein bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
tau-protein kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
NF-kappaB bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
protein serine kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (37)

Processvia Protein(s)Taxonomy
chromosome, telomeric regionDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nucleusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nucleoplasmDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nucleolusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
cytosolDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
membraneDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA-dependent protein kinase complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
chromatinDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
transcription regulator complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA-dependent protein kinase-DNA ligase 4 complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
small-subunit processomeDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein-containing complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein-DNA complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nonhomologous end joining complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nucleusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
chromosome, telomeric regionSerine-protein kinase ATMHomo sapiens (human)
peroxisomal matrixSerine-protein kinase ATMHomo sapiens (human)
site of double-strand breakSerine-protein kinase ATMHomo sapiens (human)
nucleusSerine-protein kinase ATMHomo sapiens (human)
nucleoplasmSerine-protein kinase ATMHomo sapiens (human)
nucleolusSerine-protein kinase ATMHomo sapiens (human)
cytoplasmSerine-protein kinase ATMHomo sapiens (human)
peroxisomal matrixSerine-protein kinase ATMHomo sapiens (human)
centrosomeSerine-protein kinase ATMHomo sapiens (human)
spindleSerine-protein kinase ATMHomo sapiens (human)
cytosolSerine-protein kinase ATMHomo sapiens (human)
cytoplasmic vesicleSerine-protein kinase ATMHomo sapiens (human)
intracellular membrane-bounded organelleSerine-protein kinase ATMHomo sapiens (human)
DNA repair complexSerine-protein kinase ATMHomo sapiens (human)
cytoplasmSerine-protein kinase ATMHomo sapiens (human)
nucleusSerine-protein kinase ATMHomo sapiens (human)
chromosome, telomeric regionSerine/threonine-protein kinase ATRHomo sapiens (human)
nuclear envelopeSerine/threonine-protein kinase ATRHomo sapiens (human)
site of DNA damageSerine/threonine-protein kinase ATRHomo sapiens (human)
nucleusSerine/threonine-protein kinase ATRHomo sapiens (human)
nucleoplasmSerine/threonine-protein kinase ATRHomo sapiens (human)
chromosomeSerine/threonine-protein kinase ATRHomo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase ATRHomo sapiens (human)
PML bodySerine/threonine-protein kinase ATRHomo sapiens (human)
ATR-ATRIP complexSerine/threonine-protein kinase ATRHomo sapiens (human)
nucleusSerine/threonine-protein kinase ATRHomo sapiens (human)
chromosomeSerine/threonine-protein kinase ATRHomo sapiens (human)
glutamatergic synapseGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleoplasmGlycogen synthase kinase-3 betaHomo sapiens (human)
cytoplasmGlycogen synthase kinase-3 betaHomo sapiens (human)
mitochondrionGlycogen synthase kinase-3 betaHomo sapiens (human)
centrosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 betaHomo sapiens (human)
plasma membraneGlycogen synthase kinase-3 betaHomo sapiens (human)
axonGlycogen synthase kinase-3 betaHomo sapiens (human)
dendriteGlycogen synthase kinase-3 betaHomo sapiens (human)
beta-catenin destruction complexGlycogen synthase kinase-3 betaHomo sapiens (human)
presynapseGlycogen synthase kinase-3 betaHomo sapiens (human)
postsynapseGlycogen synthase kinase-3 betaHomo sapiens (human)
Wnt signalosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 betaHomo sapiens (human)
axonGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
cytoplasmGlycogen synthase kinase-3 betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (55)

Assay IDTitleYearJournalArticle
AID1168391Cytotoxicity against human HL60/MDR cells assessed as viable cells at 25 uM after 48 hrs by WST assay2014Journal of natural products, Oct-24, Volume: 77, Issue:10
Identification of key structural characteristics of Schisandra chinensis lignans involved in P-glycoprotein inhibition.
AID678830TP_TRANSPORTER: inhibition of VCR transport in HL60/MRP cells2007Life sciences, Jan-30, Volume: 80, Issue:8
Dibenzocyclooctadiene lignans: a class of novel inhibitors of multidrug resistance-associated protein 1.
AID1168390Potentiation of 0.6 uM doxorubicin-induced cytotoxicity in human HL60/MDR cells assessed as viable cells at 25 uM after 48 hrs by WST assay relative to control2014Journal of natural products, Oct-24, Volume: 77, Issue:10
Identification of key structural characteristics of Schisandra chinensis lignans involved in P-glycoprotein inhibition.
AID593233Inhibition of DNAPK after 2 hrs by radiometric phosphate incorporation assay2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
AID678828TP_TRANSPORTER: inhibition of VP-16 transport in HL60/MRP cells2007Life sciences, Jan-30, Volume: 80, Issue:8
Dibenzocyclooctadiene lignans: a class of novel inhibitors of multidrug resistance-associated protein 1.
AID1418398Inhibition of P-gp in human KBv200 cells assessed as potentiation of vincristine-induced cytotoxicity by measuring reduction in vincristine IC50 at 25 uM after 96 hrs by Western blot analysis relative to vincristine alone2018European journal of medicinal chemistry, Nov-05, Volume: 159Discovery of traditional Chinese medicine monomers and their synthetic intermediates, analogs or derivatives for battling P-gp-mediated multi-drug resistance.
AID593187Inhibition of full length recombinant ATR after 24 hrs by radiometric phosphate incorporation assay2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
AID1168387Inhibition of P-gp-mediated doxorubicin efflux in human HL60/MDR cells assessed as intracellular doxorubicin accumulation at 25 uM preincubated for 15 mins measured after 60 mins by flow cytometry2014Journal of natural products, Oct-24, Volume: 77, Issue:10
Identification of key structural characteristics of Schisandra chinensis lignans involved in P-glycoprotein inhibition.
AID682028TP_TRANSPORTER: inhibition of DNR transport in HL60/ADR cells (overexpression of MRP1)2007Life sciences, Jan-30, Volume: 80, Issue:8
Dibenzocyclooctadiene lignans: a class of novel inhibitors of multidrug resistance-associated protein 1.
AID678832TP_TRANSPORTER: inhibition of DNR transport in HL60/MRP cells2007Life sciences, Jan-30, Volume: 80, Issue:8
Dibenzocyclooctadiene lignans: a class of novel inhibitors of multidrug resistance-associated protein 1.
AID678831TP_TRANSPORTER: inhibition of VCR transport in HL60/ADR cells (overexpression of MRP1)2007Life sciences, Jan-30, Volume: 80, Issue:8
Dibenzocyclooctadiene lignans: a class of novel inhibitors of multidrug resistance-associated protein 1.
AID1168389Potentiation of 0.2 uM doxorubicin-induced cytotoxicity in human HL60/MDR cells assessed as viable cells at 25 uM after 48 hrs by WST assay relative to control2014Journal of natural products, Oct-24, Volume: 77, Issue:10
Identification of key structural characteristics of Schisandra chinensis lignans involved in P-glycoprotein inhibition.
AID705439Inhibition of flag-tagged ATR expressed in HEK293T cells using PHAS-1 as substrate after 20 mins by autoradiography2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family.
AID1168388Potentiation of 0.02 uM doxorubicin-induced cytotoxicity in human HL60/MDR cells assessed as viable cells at 25 uM after 48 hrs by WST assay relative to control2014Journal of natural products, Oct-24, Volume: 77, Issue:10
Identification of key structural characteristics of Schisandra chinensis lignans involved in P-glycoprotein inhibition.
AID593232Inhibition of full length recombinant ATM after 24 hrs by radiometric phosphate incorporation assay2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
AID678829TP_TRANSPORTER: inhibition of VP-16 transport in HL60/ADR cells (overexpression of MRP1)2007Life sciences, Jan-30, Volume: 80, Issue:8
Dibenzocyclooctadiene lignans: a class of novel inhibitors of multidrug resistance-associated protein 1.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID779150Inhibition of Wnt/beta-catenin signaling pathway in human HEK293 cells at 20 uM after 24 hrs by dual luciferase reporter gene assay relative to vehicle-treated control2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Anti-proliferative activity of hydnocarpin, a natural lignan, is associated with the suppression of Wnt/β-catenin signaling pathway in colon cancer cells.
AID313796Antiproliferative activity against human SNU638 cells after 72 hrs by SRB assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Antiproliferative effects of dibenzocyclooctadiene lignans isolated from Schisandra chinensis in human cancer cells.
AID380427Cytotoxicity against human SK-MEL cells upto 48 uM2006Journal of natural products, Mar, Volume: 69, Issue:3
Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans.
AID313797Antiproliferative activity against human T47D cells after 72 hrs by SRB assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Antiproliferative effects of dibenzocyclooctadiene lignans isolated from Schisandra chinensis in human cancer cells.
AID380424Cytotoxicity against human HL60 cells by XTT assay2006Journal of natural products, Mar, Volume: 69, Issue:3
Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans.
AID1168389Potentiation of 0.2 uM doxorubicin-induced cytotoxicity in human HL60/MDR cells assessed as viable cells at 25 uM after 48 hrs by WST assay relative to control2014Journal of natural products, Oct-24, Volume: 77, Issue:10
Identification of key structural characteristics of Schisandra chinensis lignans involved in P-glycoprotein inhibition.
AID313798Antiproliferative activity against human HCT15 cells after 72 hrs by SRB assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Antiproliferative effects of dibenzocyclooctadiene lignans isolated from Schisandra chinensis in human cancer cells.
AID1168391Cytotoxicity against human HL60/MDR cells assessed as viable cells at 25 uM after 48 hrs by WST assay2014Journal of natural products, Oct-24, Volume: 77, Issue:10
Identification of key structural characteristics of Schisandra chinensis lignans involved in P-glycoprotein inhibition.
AID313800Antiproliferative activity against human A549 cells after 72 hrs by SRB assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Antiproliferative effects of dibenzocyclooctadiene lignans isolated from Schisandra chinensis in human cancer cells.
AID313795Antiproliferative activity against human SK-HEP1 cells after 72 hrs by SRB assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Antiproliferative effects of dibenzocyclooctadiene lignans isolated from Schisandra chinensis in human cancer cells.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1168406Potentiation of doxorubicin-induced cell cycle arrest in human HL60/MDR cells assessed as accumulation at S phase at 25 uM after 48 hrs by flow cytometry (Rvb = 59.0 %)2014Journal of natural products, Oct-24, Volume: 77, Issue:10
Identification of key structural characteristics of Schisandra chinensis lignans involved in P-glycoprotein inhibition.
AID1168388Potentiation of 0.02 uM doxorubicin-induced cytotoxicity in human HL60/MDR cells assessed as viable cells at 25 uM after 48 hrs by WST assay relative to control2014Journal of natural products, Oct-24, Volume: 77, Issue:10
Identification of key structural characteristics of Schisandra chinensis lignans involved in P-glycoprotein inhibition.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1872905Inhibition of human recombinant GSK3-beta2022European journal of medicinal chemistry, Jun-05, Volume: 236Development of inhibitors targeting glycogen synthase kinase-3β for human diseases: Strategies to improve selectivity.
AID380431Antiinflammatory activity against LPS-induced prostaglandin E2 production in mouse macrophages upto 25 ug/ml2006Journal of natural products, Mar, Volume: 69, Issue:3
Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans.
AID1168390Potentiation of 0.6 uM doxorubicin-induced cytotoxicity in human HL60/MDR cells assessed as viable cells at 25 uM after 48 hrs by WST assay relative to control2014Journal of natural products, Oct-24, Volume: 77, Issue:10
Identification of key structural characteristics of Schisandra chinensis lignans involved in P-glycoprotein inhibition.
AID380426Cytotoxicity against pig LLC-PK1 cells upto 48 uM2006Journal of natural products, Mar, Volume: 69, Issue:3
Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans.
AID313794Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Antiproliferative effects of dibenzocyclooctadiene lignans isolated from Schisandra chinensis in human cancer cells.
AID1371179Substrate activity at CYP3A4 (unknown origin) assessed as enzyme-mediated compound turnover assessed per pmol protein at 10 uM2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
A Naturally Occurring Isoform-Specific Probe for Highly Selective and Sensitive Detection of Human Cytochrome P450 3A5.
AID1371180Substrate activity at CYP3A5 (unknown origin) assessed as enzyme-mediated compound turnover assessed per pmol protein at 10 uM2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
A Naturally Occurring Isoform-Specific Probe for Highly Selective and Sensitive Detection of Human Cytochrome P450 3A5.
AID1168401Cell cycle arrest in human HL60/MDR cells assessed as accumulation at G1 phase at 25 uM after 48 hrs by flow cytometry (Rvb = 59.0 %)2014Journal of natural products, Oct-24, Volume: 77, Issue:10
Identification of key structural characteristics of Schisandra chinensis lignans involved in P-glycoprotein inhibition.
AID1168387Inhibition of P-gp-mediated doxorubicin efflux in human HL60/MDR cells assessed as intracellular doxorubicin accumulation at 25 uM preincubated for 15 mins measured after 60 mins by flow cytometry2014Journal of natural products, Oct-24, Volume: 77, Issue:10
Identification of key structural characteristics of Schisandra chinensis lignans involved in P-glycoprotein inhibition.
AID1332258Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay2017Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
Biotransformation of isofraxetin-6-O-β-d-glucopyranoside by Angelica sinensis (Oliv.) Diels callus.
AID313799Antiproliferative activity against human K562 cells after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Antiproliferative effects of dibenzocyclooctadiene lignans isolated from Schisandra chinensis in human cancer cells.
AID380430Cytotoxicity against human SKOV3 cells upto 48 uM2006Journal of natural products, Mar, Volume: 69, Issue:3
Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans.
AID1168403Cell cycle arrest in human HL60/MDR cells assessed as accumulation at S phase at 25 uM after 48 hrs by flow cytometry (Rvb = 29.9 %)2014Journal of natural products, Oct-24, Volume: 77, Issue:10
Identification of key structural characteristics of Schisandra chinensis lignans involved in P-glycoprotein inhibition.
AID380425Cytotoxicity against african green monkey Vero cells upto 48 uM2006Journal of natural products, Mar, Volume: 69, Issue:3
Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans.
AID380428Cytotoxicity against human KB cells upto 48 uM2006Journal of natural products, Mar, Volume: 69, Issue:3
Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans.
AID380429Cytotoxicity against human BT549 cells upto 48 uM2006Journal of natural products, Mar, Volume: 69, Issue:3
Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans.
AID1168405Potentiation of doxorubicin-induced cell cycle arrest in human HL60/MDR cells assessed as accumulation at G2/M phase at 25 uM after 48 hrs by flow cytometry (Rvb = 59.0 %)2014Journal of natural products, Oct-24, Volume: 77, Issue:10
Identification of key structural characteristics of Schisandra chinensis lignans involved in P-glycoprotein inhibition.
AID380432Inhibition of COX2 in mouse macrophages2006Journal of natural products, Mar, Volume: 69, Issue:3
Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans.
AID380423Antioxidant activity in human HL60 cells assessed as inhibition of TPA-stimulated hydrogen peroxide induced DCFH-DA oxidation by fluorometric microplate assay2006Journal of natural products, Mar, Volume: 69, Issue:3
Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans.
AID1168402Cell cycle arrest in human HL60/MDR cells assessed as accumulation at G2/M phase at 25 uM after 48 hrs by flow cytometry (Rvb = 11.3 %)2014Journal of natural products, Oct-24, Volume: 77, Issue:10
Identification of key structural characteristics of Schisandra chinensis lignans involved in P-glycoprotein inhibition.
AID1168404Potentiation of doxorubicin-induced cell cycle arrest in human HL60/MDR cells assessed as accumulation at G1 phase at 25 uM after 48 hrs by flow cytometry (Rvb = 59.0 %)2014Journal of natural products, Oct-24, Volume: 77, Issue:10
Identification of key structural characteristics of Schisandra chinensis lignans involved in P-glycoprotein inhibition.
AID1129459Hepatoprotective activity against carbon tetrachloride-induced toxicity in human HL-7702 cells assessed as increase of cell survival rate at 0.2 ug/ul pretreated for 12 hrs before carbon tetrachloride addition by MTS assay relative to control2014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Synthesis and the hepatoprotective activity of dibenzocyclooctadiene lignan derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (323)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (2.79)18.7374
1990's19 (5.88)18.2507
2000's57 (17.65)29.6817
2010's177 (54.80)24.3611
2020's61 (18.89)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 14.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index14.55 (24.57)
Research Supply Index5.78 (2.92)
Research Growth Index5.24 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (14.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.31%)5.53%
Trials0 (0.00%)5.53%
Reviews7 (2.18%)6.00%
Reviews1 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other313 (97.51%)84.16%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]